Mergers & Acquisitions

TPG Makes Significant Strategic Growth Investment in K2 Medical Research

6516 TPG Growth - K2 Medical Research SP

M&A Engagement Overview 

Industry Group: Healthcare & Life Sciences
Area of Focus: Pharma Services


Harris Williams advised TPG on their significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform specializing in central nervous system trials for pharma and biotech sponsors. 

TPG has extensive experience investing across the healthcare space and focuses on companies that add value to the healthcare system and enable better patient outcomes, like K2. They will be an ideal partner for K2 as the company continues to execute on their goal of building a multi-regional integrated site platform.


K2 successfully differentiated themselves within the clinical trial site sector by having developed direct relationships with pharma and biotech sponsors while also executing an impressive de novo regional growth strategy. 


The sector is a critical link of the value chain for clinical trials. It is highly fragmented and predominantly includes small, founder-run businesses. Consolidation and professionalization within the segment create efficiencies and cost savings throughout the clinical trial process. 

TPG brings significant expertise investing in leading healthcare companies. Partnering with K2 will allow the company to accelerate their strong momentum and continue to offer innovative and practical solutions to the patients they serve. 

Contact the Harris Williams Healthcare & Life Sciences Group to learn more about this client engagement.